Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR

by · The Markets Daily

Moody Aldrich Partners LLC grew its stake in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 62.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,716 shares of the biopharmaceutical company’s stock after acquiring an additional 28,304 shares during the period. Moody Aldrich Partners LLC owned 0.39% of Nektar Therapeutics worth $4,194,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Acadian Asset Management LLC increased its holdings in shares of Nektar Therapeutics by 1.4% in the first quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company’s stock valued at $4,961,000 after purchasing an additional 100,645 shares in the last quarter. Almitas Capital LLC increased its stake in shares of Nektar Therapeutics by 401.1% in the 1st quarter. Almitas Capital LLC now owns 4,610,872 shares of the biopharmaceutical company’s stock valued at $3,135,000 after buying an additional 3,690,647 shares during the period. AQR Capital Management LLC increased its stake in shares of Nektar Therapeutics by 336.9% in the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 2,807,595 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Nektar Therapeutics by 14.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 3,007,928 shares of the biopharmaceutical company’s stock worth $2,045,000 after acquiring an additional 380,967 shares during the last quarter. Finally, Ieq Capital LLC lifted its stake in shares of Nektar Therapeutics by 2,435.4% during the first quarter. Ieq Capital LLC now owns 557,222 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 535,244 shares during the period. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday. Wall Street Zen cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. BTIG Research increased their price objective on shares of Nektar Therapeutics from $100.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. B. Riley raised their price objective on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. Finally, HC Wainwright upped their target price on shares of Nektar Therapeutics from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $111.83.

Get Our Latest Research Report on Nektar Therapeutics

Nektar Therapeutics Trading Up 0.9%

NASDAQ:NKTR opened at $42.28 on Thursday. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $66.92. The stock has a market cap of $859.98 million, a price-to-earnings ratio of -5.31 and a beta of 1.27. The stock has a 50-day moving average price of $55.15 and a two-hundred day moving average price of $42.31.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.85) EPS for the quarter, topping analysts’ consensus estimates of ($2.85) by $1.00. The business had revenue of $11.79 million for the quarter, compared to analyst estimates of $10.20 million. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. Sell-side analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Insider Activity

In related news, CEO Howard W. Robin sold 2,207 shares of Nektar Therapeutics stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total value of $119,795.96. Following the sale, the chief executive officer owned 54,245 shares of the company’s stock, valued at approximately $2,944,418.60. This trade represents a 3.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Zalevsky sold 1,157 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total transaction of $62,801.96. Following the completion of the sale, the insider directly owned 18,971 shares in the company, valued at approximately $1,029,745.88. This represents a 5.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,994 shares of company stock worth $216,794 over the last three months. Corporate insiders own 5.25% of the company’s stock.

Nektar Therapeutics Profile

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.

Featured Articles